CSIMarket
 


Tango Therapeutics Inc   (TNGX)
Other Ticker:  
 

Cumulative Tango Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

TNGX's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

TNGX Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -15.4 % 20.03 % 36.88 % 36.51 % 22.24 %
Y / Y Current Assets Growth -7.66 % -26.5 % -25.54 % -23.78 % -22.21 %
Working Capital Ratio for Trailing Twelve Months Period 6.83 6.73 7.58 8.77 10.18
Total Ranking # 474 # 522 # 525 # 491 # 449
Seq. Current Liabilities Growth -19.05 % -0.07 % -3.37 % 8.23 % 14.86 %
Seq. Current Assets Growth 15.71 % -6.55 % -8.6 % -6.57 % -7.89 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Current Liabilities decreased faster than Tango Therapeutics Inc 's average Current Assets, this led to increase in in Tango Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period to 6.83, Working Capital Ratio for Trailing Twelve Months Period remained below Tango Therapeutics Inc average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 139 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Tango Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about TNGX
Working Capital Ratio TNGX in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 140
Sector # 223
S&P 500 # 338


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
12.03 9.19 6.73
(Mar 31 2022)   (Jun 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Lixte Biotechnology Holdings Inc   18.41 
Viking Therapeutics Inc   18.05 
Agios Pharmaceuticals Inc   17.73 
Immuneering Corporation  17.57 
Cymabay Therapeutics Inc   17.53 
Zomedica Corp   17.50 
Cohbar Inc   17.47 
Acrivon Therapeutics Inc   17.40 
Akouos inc   17.30 
Pasithea Therapeutics Corp   17.26 
Structure Therapeutics Inc   16.99 
Pliant Therapeutics Inc   16.88 
Lipocine Inc   16.80 
Pardes Biosciences Inc   16.63 
Anixa Biosciences Inc   16.52 
Iveric Bio Inc   16.49 
Medicinova Inc   16.39 
Nanoviricides inc   16.34 
Fulcrum Therapeutics Inc   16.26 
Sagimet Biosciences inc   16.19 
Verve Therapeutics Inc   15.91 
Lyell Immunopharma Inc   15.88 
Ovid Therapeutics Inc   15.62 
Verona Pharma Plc  15.46 
Rallybio Corporation  15.36 
Ideaya Biosciences Inc   15.24 
Anebulo Pharmaceuticals Inc   14.89 
Olema Pharmaceuticals inc   14.82 
Cryoport inc   14.81 
Oric Pharmaceuticals Inc   14.64 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com